Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2011, with a specific announcement date of May 18, 2011. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 375,000 Ordinary shares of 25 pence each.
- Purchase Price Range: Highest price of 1,323.00 pence per share; lowest price of 1,314.50 pence per share.
- Treasury Holdings (Settled): 493,224,284 shares (8.72% of total issued share capital).
- Treasury Holdings (Including Unsettled): 494,449,284 shares (9.58% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,163,149,420 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 375,000 shares on May 18, 2011. Consequently, the percentage of total voting rights held in Treasury increased to 9.58% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares in issue (5,163,149,420) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (9.58% including unsettled shares).
- Review the price paid per share (1,314.50 to 1,323.00 pence) against market prices on May 18, 2011.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.